Photo from /LinkedIn
Sep 17, 2024, 21:50
Late-breaking primary results from the DESTINYBreast-12 trial at ESMO24
ESMO posted on LinkedIn:
“At ESMO24, late-breaking primary results from the DESTINYBreast-12 trial revealed substantial and durable efficacy with the antibody–drug conjugate (ADC) trastuzumab deruxtecan in patients with HER2+ metastatic Breast Cancer, including those with brain metastases. Encouraging data were also presented from the smaller ICARUS-BREAST01 study with the novel anti-HER3 ADC patritumab deruxtecan in patients with HR+/HER2- Advanced Breast Cancer after failure of CDK-4/6 inhibitor therapy.
Read the full-data commentary by Philippe Aftimos on the ESMO Daily Reporter.”
Source: ESMO/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14